Find an Article

Filter articles

Applied Filters

Showing 221 to 230 of 338 results

Finding a cure: how big pharma can tackle counterfeiting

International, US25-02-2016Stephen Ward

Counterfeiting poses one of the greatest threats to the pharmaceutical industry, but there are good reasons to believe that companies are tackling the problem head on. Stephen Ward of Pinkerton reports.

How Justice Scalia helped to shape US IP law


During nearly 30 years as a US Supreme Court justice, Antonin Scalia had the unenviable tasks of ruling on homosexuality, the right to carry hand guns, and abortion. Nevertheless, it was a mystery patent case that proved the most difficult. WIPR looks back at some of the most important IP cases of the past few years and how Scalia voted on them.

How to succeed in the business of biotech patentability

US11-02-2016Kathryn Hull

Following several high-profile decisions by the US Supreme Court making it harder to patent biotech inventions, parties should follow several best practices to give their products the best chance of being patented. Kathryn Hull of Gordon Rees provides some tips.

Diagnostics patent eligibility: a turning point approaches

US27-01-2016Jenny Shmuel and Megan Chacon

As reflected in numerous recent court opinions, the broad Supreme Court rulings of Mayo, Myriad and Alice have drastically changed the landscape of patent-eligibility in diagnostics. Jenny Shmuel and Megan Chacon of Fish & Richardson review the situation and discuss some future scenarios.

Patentability of diagnostics: reasons for optimism

US21-01-2016Kevin O’Connor

Despite the current unfavourable climate, there is still reason to be optimistic about patenting diagnostic method claims in the US, particularly if the claim is focused on a particular disease, biomarker, and/or treatment and includes an active step that applies the diagnostic information, says Kevin O’Connor of Neal, Gerber & Eisenberg.

Healthy farms, healthy planet

International11-01-2016Graham Dutfield

Intellectual property rights should be used to help valorise agricultural biodiversity and traditional knowledge for the benefit of the global population as well as small farming communities around the world, says Graham Dutfield of the University of Leeds.

Pharma innovators in Canada: is utility standard uncertainty worth the risk?

Canada07-01-2016Declan Hamill and Megan Kendall

The manner in which some Canadian judges have applied the ‘promise’ doctrine has been criticised as arbitrary and subjective, note Declan Hamill and Megan Kendall of Innovative Medicines Canada, the association of Canada’s innovative pharmaceutical industry.

Jawbone v Fitbit: will fitness trackers be the next IP war?

US22-12-2015Fabio Marino and Luc Dahlin

The smartphone wars may have slowed down but many smaller high-tech companies continue to assert their IP rights against competitors, as the fitness tracker battle shows. Fabio Marino and Luc Dahlin of McDermott Will & Emery report.

To dance or not to dance: biosimilar strategies post Amgen v Sandoz

US03-12-2015Gerard Norton and Michael Montgomery

Following the Federal Circuit’s ruling in Amgen v Sandoz, biosimilar applicants should weigh up several factors when deciding whether to opt into the so-called patent dance. Gerard Norton and Michael Montgomery of Fox Rothschild discuss the potential strategies.

Court reports: Warner-Lambert v Sandoz

US26-11-2015Varuni Paranavitane

Sandoz has brought to market its generic pregabalin product with a full label in the UK and a skinny label in France. Varuni Paranavitane of Osborne Clarke reports on court rulings in the UK, and most recently France, on actions brought by Warner-Lambert against Sandoz.

Showing 221 to 230 of 338 results